Newron Advances Global Enrollment Despite U.S. Clinical Hold

Newron Pharmaceuticals said it received the anticipated written communication from the U.S. FDA regarding the clinical hold on U.S. study sites in the Phase 3 ENIGMA-TRS2 trial of Evenamide. The article does not disclose the communication’s contents or any change to the hold.